A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"?
With the advent and stunning success of combination antiretroviral therapy (ART) to prolong and improve quality of life for persons with HIV infection, HIV research has been afforded the opportunity to pivot towards studies aimed at finding "a cure." The mere idea that cure of HIV might be possible has energized researchers and the community towards achieving this goal. Funding agencies, both governmental and private, have targeted HIV cure as a high priority; many in the field have responded to these initiatives and the cure research agenda is robust. In this "salon" two editors ofPathogens and Immunity, Michael Lederman and Daniel Douek ask whether curing HIV is a realistic, scalable objective. We start with an overview perspective and have asked a number of prominent HIV researchers to add to the discussion.
Case Western Reserve University School of Medicine, Cleveland, OH.
Michael M
MM
Lederman
University of Southern California, Los Angeles, CA.
Paula M
PM
Cannon
University of California, Los Angeles, Los Angeles, CA.
Judith S
JS
Currier
University of Pennsylvania, Philadelphia, PA.
Carl H
CH
June
Fred Hutchinson Cancer Research Center, Seattle, WA.
Hans Peter
HP
Kiem
Fred Hutchinson Cancer Research Center, Seattle, WA.
Daniel R
DR
Kuritzkes
The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia.
Sharon R
SR
Lewin
University of North Carolina at Chapel Hill, Chapel Hill, NC.
David M
DM
Margolis
University of California, San Francisco, San Francisco, CA.
Joseph M
JM
McCune
University of Pittsburgh, Pittsburgh, PA.
John W
JW
Mellors
University of Minnesota, Minneapolis, MN.
Timothy W
TW
Schacker
Case Western Reserve University School of Medicine, Cleveland, OH.
Rafick P
RP
Sekaly
University of Pennsylvania, Philadelphia, PA.
Pablo
P
Tebas
Harvard University and Massachusetts Institute of Technology, Cambridge, MA.
Bruce D
BD
Walker
Vaccine Research Center, National Institutes of Health, Bethesda, MD.
Daniel C
DC
Douek
Berlin Patient; CCR5; HIV; cure; elite controller; eradication; functional cure; inflammation; latency; procoagulant; reservoir
AIDS. 2014 May 15;28(8):1193-202
24556869
N Engl J Med. 2014 Mar 6;370(10):901-10
24597865
J Infect Dis. 2014 Aug 15;210(4):619-29
24585897
Blood. 2003 Apr 1;101(7):2711-20
12433688
Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2307-12
24469825
PLoS Pathog. 2014 May 15;10(5):e1004078
24831517
J Infect Dis. 2011 Oct 15;204(8):1217-26
21917895
J Virol. 2009 Jan;83(1):329-35
18945778
J Infect Dis. 2014 Oct 15;210(8):1248-59
24795473
N Engl J Med. 2009 Feb 12;360(7):692-8
19213682
J Infect Dis. 2008 Jan 1;197(1):126-33
18171295
J Infect Dis. 2008 Feb 15;197(4):563-71
18275276
N Engl J Med. 2014 Dec 18;371(25):2437-8
25517721
AIDS. 2005 Dec 2;19(18):2169-71
16284469
AIDS. 2015 May 15;29(8):867-76
25730507
J Infect Dis. 2014 Oct 15;210(8):1228-38
24755434
Nature. 2006 Sep 21;443(7109):350-4
16921384
PLoS Pathog. 2013 Mar;9(3):e1003211
23516360
Blood. 2011 May 12;117(19):5142-51
21436070
J Infect Dis. 2013 Jun 1;207(11):1694-702
23460751